menu
    • menu

    Company profile for AgomAb Therapeutics N.V

    NEW Drugs in Dev: 4
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AgomAb is developing molecular therapies for the regeneration of damaged tissues. Our unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.The AgomAb team has selected the most promising lead antibodies and continues to generate preclinical ...
    AgomAb is developing molecular therapies for the regeneration of damaged tissues. Our unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.The AgomAb team has selected the most promising lead antibodies and continues to generate preclinical data that support the use of these antibodies in fibrotic, inflammatory, autoimmune and degenerative diseases. We are committed to advancing these molecules into clinical development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AgomAb Therapeutics N.VBelgium Flag
    Country
    Country
    Belgium
    Address
    Address
    Pieter Van Reysschootlaan 2/104 9051 Sint-Denijs-Westrem (Gent)
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://agomab.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AgomAb To Participate In Upcoming Conferences
    AgomAb To Participate In Upcoming Conferences

    14 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/14/3294788/0/en/agomab-to-participate-in-upcoming-conferences.html

    GLOBENEWSWIRE
    14 May 2026
    Share Share
    Agomab Releases 2025 Financials, Affirms 2026 Forecast
    Agomab Releases 2025 Financials, Affirms 2026 Forecast

    23 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/23/3280465/0/en/agomab-reports-full-year-2025-financial-results-and-confirms-2026-outlook.html

    GLOBENEWSWIRE
    23 Apr 2026
    Share Share
    Agomab Secures U.S. Patent for Inhaled ALK5 Inhibitor AGMB-447
    Agomab Secures U.S. Patent for Inhaled ALK5 Inhibitor AGMB-447

    26 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/26/3262841/0/en/Agomab-Receives-U-S-Patent-for-AGMB-447-its-Inhaled-Lung-restricted-Small-Molecule-Inhibitor-of-ALK5-in-Development-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html

    GLOBENEWSWIRE
    26 Mar 2026
    Share Share
    Agomab Announces Closing Of Initial Public Offering
    Agomab Announces Closing Of Initial Public Offering

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234901/0/en/Agomab-Announces-Closing-of-Initial-Public-Offering.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    AgomAB Announces Pricing Of Initial Public Offering
    AgomAB Announces Pricing Of Initial Public Offering

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/06/3233537/0/en/Agomab-Announces-Pricing-of-Initial-Public-Offering.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Agomab Announces Launch Of Initial Public Offering
    Agomab Announces Launch Of Initial Public Offering

    02 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/02/3230139/0/en/Agomab-Announces-Launch-of-Initial-Public-Offering.html

    GLOBENEWSWIRE
    02 Feb 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search